{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:08:40Z","timestamp":1788876520166,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jneuroim.2026.579053","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T23:01:56Z","timestamp":1785538916000},"page":"579053","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Plasma IL-24 is associated with time to first fall in Parkinson's disease"],"prefix":"10.1016","volume":"420","author":[{"given":"Kazuhiro","family":"Iwaoka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayuri","family":"Oikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyoshi","family":"Toyoshiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2026.579053_bb0005","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","article-title":"Criteria for the diagnosis of corticobasal degeneration","volume":"80","author":"Armstrong","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2026.579053_bb0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095192","article-title":"Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability","volume":"9","author":"Assarsson","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jneuroim.2026.579053_bb0015","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. R. Stat. Soc. Ser. B Stat Methodol."},{"key":"10.1016\/j.jneuroim.2026.579053_bb0020","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.parkreldis.2015.11.007","article-title":"Risk and course of motor complications in a population-based incident Parkinson\u2019s disease cohort","volume":"22","author":"Bjornestad","year":"2016","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.jneuroim.2026.579053_bb0025","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/mds.29683","article-title":"A statement of the MDS on biological definition, staging, and classification of Parkinson\u2019s disease","volume":"39","author":"Cardoso","year":"2024","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jneuroim.2026.579053_bb0030","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1146\/annurev-immunol-051116-052358","article-title":"Microglia function in the central nervous system during health and neurodegeneration","volume":"35","author":"Colonna","year":"2017","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jneuroim.2026.579053_bb0035","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.neuron.2014.02.040","article-title":"Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain","volume":"82","author":"Elmore","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.jneuroim.2026.579053_bb0040","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/mds.21507","article-title":"Clinical diagnostic criteria for dementia associated with Parkinson\u2019s disease","volume":"22","author":"Emre","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jneuroim.2026.579053_bb0045","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/jamaneurol.2015.0703","article-title":"New clinical subtypes of Parkinson disease and their longitudinal progression: a multicentre prospective study","volume":"72","author":"Fereshtehnejad","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jneuroim.2026.579053_bb0050","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10286-011-0119-5","article-title":"Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome","volume":"21","author":"Freeman","year":"2011","journal-title":"Clin. Auton. Res."},{"key":"10.1016\/j.jneuroim.2026.579053_bb0055","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","article-title":"Second consensus statement on the diagnosis of multiple system atrophy","volume":"71","author":"Gilman","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2026.579053_bb0060","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/mds.21956","article-title":"The Sydney multicenter study of Parkinson\u2019s disease: the inevitability of dementia at 20 years","volume":"23","author":"Hely","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jneuroim.2026.579053_bb0065","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1474-4422(09)70062-6","article-title":"Neuroinflammation in Parkinson\u2019s disease: a target for neuroprotection?","volume":"8","author":"Hirsch","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2026.579053_bb0070","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/mds.26987","article-title":"Clinical diagnosis of progressive supranuclear palsy: the Movement Disorder Society criteria","volume":"32","author":"H\u00f6glinger","year":"2017","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jneuroim.2026.579053_bb0075","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1474-4422(23)00404-0","article-title":"A biological classification of Parkinson\u2019s disease: the SynNeurGe research diagnostic criteria","volume":"23","author":"H\u00f6glinger","year":"2024","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2026.579053_bb0080","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1212\/WNL.40.10.1529","article-title":"Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort","volume":"40","author":"Jankovic","year":"1990","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2026.579053_bb0085","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson's disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jneuroim.2026.579053_bb0090","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/384467a0","article-title":"Neurturin, a relative of glial-cell-line-derived neurotrophic factor","volume":"384","author":"Kotzbauer","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.jneuroim.2026.579053_bb0095","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.immuni.2013.10.009","article-title":"Tumor necrosis factor receptor signaling in keratinocytes triggers interleukin-24\u2013dependent psoriasis-like skin inflammation in mice","volume":"39","author":"Kumari","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.jneuroim.2026.579053_bb0100","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/WCO.0000000000000219","article-title":"Subtypes of Parkinson\u2019s disease: state of the field and future directions","volume":"28","author":"Marras","year":"2015","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.jneuroim.2026.579053_bb0105","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1096\/fj.201900567RR","article-title":"Pharmacological inhibition of CSF1R by GW2580 reduces microglial proliferation and is protective against neuroinflammation and dopaminergic neurodegeneration","volume":"34","author":"Neal","year":"2020","journal-title":"FASEB J."},{"key":"10.1016\/j.jneuroim.2026.579053_bb0110","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3233\/JPD-202310","article-title":"Cerebrospinal fluid profiles in Parkinson\u2019s disease: no accumulation of glucosylceramide, but significant downregulation of active complement C5 fragment","volume":"11","author":"Niimi","year":"2021","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.jneuroim.2026.579053_bb0115","author":"Olink Proteomics"},{"key":"10.1016\/j.jneuroim.2026.579053_bb0120","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17060869","article-title":"Mechanism of action and applications of interleukin 24 in immunotherapy","volume":"17","author":"Persaud","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jneuroim.2026.579053_bb0125","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson\u2019s disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jneuroim.2026.579053_bb0130","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1212\/WNL.0000000000006737","article-title":"Age and time course of long-term motor and nonmotor complications in Parkinson disease","volume":"92","author":"Prange","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2026.579053_bb0135","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1001\/jamaneurol.2016.2742","article-title":"Aberrations in peripheral inflammatory cytokine levels in Parkinson disease: a systematic review and meta-analysis","volume":"73","author":"Qin","year":"2016","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jneuroim.2026.579053_bb0140","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.parkreldis.2005.06.011","article-title":"Caregiver-burden in Parkinson\u2019s disease is closely associated with psychiatric symptoms, falls, and disability","volume":"12","author":"Schrag","year":"2006","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.jneuroim.2026.579053_bb0145","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S1474-4422(23)00405-2","article-title":"A biological definition of neuronal \u03b1-synuclein disease: towards an integrated staging system for research","volume":"23","author":"Simuni","year":"2024","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2026.579053_bb0150","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41577-022-00684-6","article-title":"Inflammation and immune dysfunction in Parkinson disease","volume":"22","author":"Tansey","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jneuroim.2026.579053_bb0155","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1002\/mds.23429","article-title":"Systematic review of levodopa dose equivalency reporting in Parkinson\u2019s disease","volume":"25","author":"Tomlinson","year":"2010","journal-title":"Mov. Disord."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016557282600202X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016557282600202X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T13:24:12Z","timestamp":1788873852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016557282600202X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":31,"alternative-id":["S016557282600202X"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2026.579053","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasma IL-24 is associated with time to first fall in Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2026.579053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"579053"}}